Immune Checkpoint Inhibitor
Phase 3Small molecule
Immune Checkpoint Inhibitor is one of 498 small molecule programs targeting Toxicity. It is currently in Phase 3.
17
Indications
33
Total Trials
19
Active Trials
497
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Rilvegostomig
AstraZenecaPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunotherapy2 trials
Priming Immunotherapy in Advanced Disease With Radiation
Completed·—·Phase 2·NCT03313804·76 enrolled
Hepatocellular Carcinoma2 trials
Lung Cancer2 trials
Immune Checkpoint Inhibitors2 trials
Non-Small Cell Lung Cancer2 trials
22 more indications
Immune Checkpoint Inhibitor2 trials
Adenocarcinoma1 trial
Metastatic NSCLC1 trial
Lymphoma1 trial
Immune-related Adverse Events1 trial
Toxicity1 trial
Advanced/Metastatic Solid Tumors1 trial
Advanced or Metastatic Solid Tumors1 trial
Breast Cancer1 trial
Graft Rejection1 trial
Solid Tumor Malignancies1 trial
Colorectal Cancer1 trial
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Recruiting·—·Phase 2·NCT06154538·170 enrolled
Clinical Trial1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immune Checkpoint Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IImmuneSensor Therapeutics Inc.